The economic value of self-administered subcutaneous immunoglobulin G (SCIg) in Canada: a scoping review
SCIg represents an important treatment option both for alleviating burden to the Canadian healthcare system and for patients. Substantial cost savings were estimated by switching from IVIg to SCIg. These findings provide evidence to support healthcare decision-making from an economic perspective.
Authors
- Antoinette Cheung (ORCID: https://orcid.org/0000-0003-0335-6611)
- Stephen Betschel (ORCID: https://orcid.org/0000-0002-6631-4438)
- Stephen Mac (ORCID: https://orcid.org/0000-0003-4736-1770)
- Megan Manuel
- Aidan Giangregorio
- Romina Fakhraei
Institutions
- University of Toronto (CA)
- Unity Health System (US)
- Takeda (Canada) (CA)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1080/13696998.2026.2628450
- Primary Topic
- Immunodeficiency and Autoimmune Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00